Successful withdrawal from dobutamine by canagliflozin in a diabetic patient with stage D heart failure

Masaki Nakagaito, Shuji Joho*, Ryuichi Ushijima, Makiko Nakamura, Tadakazu Hirai, Koichiro Kinugawa

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Patients with stage D heart failure (HF) frequently become dependent on high doses of diuretics and inotropic agents. Recently, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), an oral antidiabetic agent, has been demonstrated to have favorable effects in preventing HF. However, it remains unknown whether SGLT2i is reliable for patients with decompensated HF. We experienced a case of a patient with stage D HF for whom attempting intravenous dobutamine withdrawal was difficult even after the administration of all conventional pharmacological treatment. Administration of canagliflozin produced an additive diuretic action and correction of volume overload in combination with azosemide and tolvaptan, and resulted in successful withdrawal of dobutamine. Thus, SGLT2i might be promising for the treatment of patients with congestive HF who are refractory to conventional diuretic treatment.

Original languageEnglish
Pages (from-to)978-981
Number of pages4
JournalInternational Heart Journal
Volume58
Issue number6
DOIs
StatePublished - 2017

Keywords

  • Diabetes mellitus
  • Diuretics
  • Inotropic agents
  • Sodium-glucose cotransporter 2 inhibitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Successful withdrawal from dobutamine by canagliflozin in a diabetic patient with stage D heart failure'. Together they form a unique fingerprint.

Cite this